Covalently crosslinked chitosan–astaxanthin nanoparticles: a stable, bioavailable oral delivery system with potentiated relief efficacy against chronic colitis
Journal of the Science of Food and Agriculture · 2026
DOI: 10.1002/jsfa.70895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, 2026. Verfasst von Xinwei Gong und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Biological Engineering, Shandong Provincial Key Laboratory of Biochemical Engineering, Qingdao University of Science and Technology, Qingd…. Hauptthemen laut MEDLINE: Colitis, Chitosan, Nanoparticles, Anti-Inflammatory Agents. Die Arbeit nennt 72 Literaturangaben. Gefördert von: The research was supported by the Qingdao Marine Science and Technology Center (No. 8-01 and 2022QNLM030003-4), the Taishan Scholars Program (No. tsqn202211058….
Abstract (Originalsprache)
BACKGROUND Astaxanthin (AST) has potent antioxidant and anti‐inflammatory properties; however, it is unstable and easily oxidized. RESULTS In this study, chitosan (CS) was employed to stabilize AST through covalent crosslinking to synthesize chitosan–astaxanthin (CS–AST) complex, and then self‐assembled into chitosan–astaxanthin nanoparticles (CS–ASTNPs). CS–ASTNPs showed a smooth, spherical morphology with a particle size of 102.6 ± 1.3 nm. The hydrodynamic particle size was 141.8 ± 1.7 nm with a zeta potential of 30.5 ± 1.4 mV. The encapsulation efficiency and loading capacity of AST within CS–ASTNPs were 83.6% and 46.1%, respectively. In a chronic colitis model induced by dextran sulfate sodium (DSS), CS–ASTNPs significantly improved the symptoms in mice body weight, colon length, and disease activity index (DAI) scores caused by DSS. The colon barrier was enhanced through increasing the level of the proteins ZO‐1, occludin, and MUC2. Furthermore, the overproduction of pro‐inflammatory cytokines tumor necrosis factor alpha (TNF‐α) and interleukin 1 beta (IL‐1β), and the proteins NLRP3, ASC, Caspase‐1, GSDMD, and cleaved Caspase‐1 were reduced, while the anti‐inflammatory cytokine interleukin 10 (IL‐10) increased. The oxidative response in colon tissues was suppressed via regulating the Nrf2/HO‐1 pathway. Additionally, CS–ASTNPs increased the Bacteroidetes/Firmicutes ratio and elevated the richness of beneficial bacteria norank_f__Muribaculaceae , Lactobacillus , and Akkermansiaceae . Notably, CS–ASTNPs showed significantly greater improvement than CS + AST ( P < 0.05). CONCLUSION In sum, CS–ASTNPs has significant potential for development as a functional food or as a drug for treating colitis. © 2026 Society of Chemical Industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biological Engineering, Shandong Provincial Key Laboratory of Biochemical Engineering, Qingdao University of Science and Technology, Qingdao, China.
- College of Food Science and Engineering, Qingdao Agricultural University, Qingdao, China.
ORCID-Profile: Xinwei Gong, Lu Yang, Hongyan Li
Förderung
- The research was supported by the Qingdao Marine Science and Technology Center (No. 8-01 and 2022QNLM030003-4), the Taishan Scholars Program (No. tsqn202211058…
Zitieren
APA
Gong, X., Li, H., Yang, L., Zhang, C., Che, H., Gu, Y., & Li, H. (2026). Covalently crosslinked chitosan–astaxanthin nanoparticles: a stable, bioavailable oral delivery system with potentiated relief efficacy against chronic colitis. Journal of the Science of Food and Agriculture. https://doi.org/10.1002/jsfa.70895
Vancouver
Gong X, Li H, Yang L, Zhang C, Che H, Gu Y, et al. Covalently crosslinked chitosan–astaxanthin nanoparticles: a stable, bioavailable oral delivery system with potentiated relief efficacy against chronic colitis. Journal of the Science of Food and Agriculture. 2026. doi:10.1002/jsfa.70895
BibTeX
@article{Gong2026,
author = {Gong, Xinwei and Li, Huiru and Yang, Lu and Zhang, Chuqiao and Che, Hongxia and Gu, Yuchao and Li, Hongyan},
title = {Covalently crosslinked chitosan–astaxanthin nanoparticles: a stable, bioavailable oral delivery system with potentiated relief efficacy against chronic colitis},
journal = {Journal of the Science of Food and Agriculture},
year = {2026},
doi = {10.1002/jsfa.70895}
}
EUVIMED